Skip to main content
Erschienen in: Journal of Gastroenterology 3/2012

01.03.2012 | Original Article—Liver, Pancreas, and Biliary Tract

Usefulness of differentiating metabolic syndrome into visceral fat type and subcutaneous fat type using ultrasonography in Japanese males

verfasst von: Masahiro Sogabe, Toshiya Okahisa, Shingo Hibino, Akira Yamanoi

Erschienen in: Journal of Gastroenterology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Although metabolic syndrome (MS) is likely to be associated with nonalcoholic fatty liver disease (NAFLD), visceral fat type MS and subcutaneous fat type MS have not been distinguished. In this study, we divided persons with MS into those with visceral and subcutaneous fat types by ultrasonography (US), and elucidated differences between these types of MS in Japanese males.

Methods

The subjects were 628 males with MS who underwent a medical checkup including abdominal US. We examined for the presence of fatty liver and investigated biochemical parameters, and we also made a distinction between visceral and subcutaneous fat types of MS by US.

Results

Total cholesterol (T-CHO), low-density lipoprotein cholesterol (LDL-C), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and the frequency of fatty liver were significantly higher in visceral fat type MS than in subcutaneous fat type MS. On logistic regression analysis with NAFLD (in our study, fatty liver with ALT ≥31 IU/l was defined as NAFLD) as a dependent variable, the age, body mass index (BMI), AST, and visceral fat type MS were significant risk factors for NAFLD. BMI, AST, and visceral fat type MS were predictors of an increased prevalence of NAFLD [odds ratios (ORs) = 1.903, 12.06, and 2.617; 95% confidence intervals (CIs) = 1.122–3.228, 7.053–20.61, and 1.741–3.935; p = 0.017, <0.001, and <0.001, respectively).

Conclusions

Japanese males with visceral fat type MS are more likely to have dyslipidemia, fatty liver, and liver dysfunction than those with subcutaneous fat type MS. Visceral fat type MS is one of the most significant risk factors for NAFLD in Japanese males with MS.
Literatur
1.
Zurück zum Zitat Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA. 2006;295:1549–55.PubMedCrossRef Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA. 2006;295:1549–55.PubMedCrossRef
2.
Zurück zum Zitat Islam MM, Horibe H, Kobayashi F. Current trend in prevalence of diabetes mellitus in Japan. J Epidemiol. 1999;9:155–62.PubMedCrossRef Islam MM, Horibe H, Kobayashi F. Current trend in prevalence of diabetes mellitus in Japan. J Epidemiol. 1999;9:155–62.PubMedCrossRef
3.
Zurück zum Zitat Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care. 1998;21:518–24.PubMedCrossRef Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care. 1998;21:518–24.PubMedCrossRef
4.
Zurück zum Zitat Yoshinaga M, Shimago A, Koriyama C, Nomura Y, Miyata K, Hashiguchi J, et al. Rapid increase in the prevalence of obesity in elementary school children. Int J Obes Relat Metab Disord. 2004;28:494–9.PubMedCrossRef Yoshinaga M, Shimago A, Koriyama C, Nomura Y, Miyata K, Hashiguchi J, et al. Rapid increase in the prevalence of obesity in elementary school children. Int J Obes Relat Metab Disord. 2004;28:494–9.PubMedCrossRef
5.
Zurück zum Zitat Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709–16.PubMedCrossRef Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709–16.PubMedCrossRef
6.
Zurück zum Zitat Isomaa B, Almgren P, Tuomi T, Torsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683–9.PubMedCrossRef Isomaa B, Almgren P, Tuomi T, Torsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683–9.PubMedCrossRef
7.
Zurück zum Zitat Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433–8.PubMedCrossRef Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433–8.PubMedCrossRef
8.
Zurück zum Zitat Watanabe S, Hojo M, Nagahara A. Metabolic syndrome and gastrointestinal diseases. J Gastroenterol. 2007;42:267–74.PubMedCrossRef Watanabe S, Hojo M, Nagahara A. Metabolic syndrome and gastrointestinal diseases. J Gastroenterol. 2007;42:267–74.PubMedCrossRef
9.
Zurück zum Zitat Hojo M, Nagahara A, Miyazaki A, Watanabe S. Digestive organ diseases and metabolic syndrome Nippon Shokakibyo Gakkai Zasshi (JJSG). 2008;105:1711–21 (in Japanese with English abstract). Hojo M, Nagahara A, Miyazaki A, Watanabe S. Digestive organ diseases and metabolic syndrome Nippon Shokakibyo Gakkai Zasshi (JJSG). 2008;105:1711–21 (in Japanese with English abstract).
10.
Zurück zum Zitat Trevisan M, Liu J, Muti P, Misciagna G, Menotti A, Fucci F, Risk Factors and Life Expectancy Research Group. Markers of insulin resistance and colorectal cancer mortality. Cancer Epidemiol Biomarkers Prev. 2001;10:937–41.PubMed Trevisan M, Liu J, Muti P, Misciagna G, Menotti A, Fucci F, Risk Factors and Life Expectancy Research Group. Markers of insulin resistance and colorectal cancer mortality. Cancer Epidemiol Biomarkers Prev. 2001;10:937–41.PubMed
11.
Zurück zum Zitat Colangelo LA, Gapstur SM, Gann PH, Dyer AR, Liu K. Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol Biomarkers Prev. 2002;11:385–91.PubMed Colangelo LA, Gapstur SM, Gann PH, Dyer AR, Liu K. Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol Biomarkers Prev. 2002;11:385–91.PubMed
12.
Zurück zum Zitat Bowers K, Albanes D, Limburg P, Pietinen P, Taylor P, Virtamo J, et al. A prospective study of anthropometric and clinical measurements associated with insulin resistance syndrome and colorectal cancer in male smokers. Am J Epidemiol. 2006;164:652–4.PubMedCrossRef Bowers K, Albanes D, Limburg P, Pietinen P, Taylor P, Virtamo J, et al. A prospective study of anthropometric and clinical measurements associated with insulin resistance syndrome and colorectal cancer in male smokers. Am J Epidemiol. 2006;164:652–4.PubMedCrossRef
13.
Zurück zum Zitat Medina J, Fernandez-Salazar LI, Garcia-Buey L, Moreno-Otero R. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care. 2004;27:2057–66.PubMedCrossRef Medina J, Fernandez-Salazar LI, Garcia-Buey L, Moreno-Otero R. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care. 2004;27:2057–66.PubMedCrossRef
14.
Zurück zum Zitat Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123:1705–25.PubMedCrossRef Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123:1705–25.PubMedCrossRef
15.
Zurück zum Zitat Eguchi Y, Eguchi T, Mizuta T, Ide Y, Yasutake T, Iwakiri R, et al. Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease. J Gastroenterol. 2006;41:462–9.PubMedCrossRef Eguchi Y, Eguchi T, Mizuta T, Ide Y, Yasutake T, Iwakiri R, et al. Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease. J Gastroenterol. 2006;41:462–9.PubMedCrossRef
16.
Zurück zum Zitat Ishibashi E, Eguchi Y, Eguchi T, Matsunobu A, Oza N, Nakashita S, et al. Waist circumference correlates with hepatic fat accumulation in male Japanese patients with nonalcoholic fatty liver disease, but not in females. J Gastroenterol Hepatol. 2008;23:908–13.PubMedCrossRef Ishibashi E, Eguchi Y, Eguchi T, Matsunobu A, Oza N, Nakashita S, et al. Waist circumference correlates with hepatic fat accumulation in male Japanese patients with nonalcoholic fatty liver disease, but not in females. J Gastroenterol Hepatol. 2008;23:908–13.PubMedCrossRef
17.
Zurück zum Zitat Westerbacka J, Corner A, Tiikkainen M, Tamminen M, Vehkavaara S, Hakkinen AM, et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia. 2004;47:1360–9.PubMedCrossRef Westerbacka J, Corner A, Tiikkainen M, Tamminen M, Vehkavaara S, Hakkinen AM, et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia. 2004;47:1360–9.PubMedCrossRef
18.
Zurück zum Zitat Clark JM, Diehl AM. Defining nonalcoholic fatty liver disease: implications for epidemiologic studies. Gastroenterology. 2003;124:248–50.PubMedCrossRef Clark JM, Diehl AM. Defining nonalcoholic fatty liver disease: implications for epidemiologic studies. Gastroenterology. 2003;124:248–50.PubMedCrossRef
19.
Zurück zum Zitat World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Geneva: World Health Organization; 1999. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Geneva: World Health Organization; 1999.
20.
Zurück zum Zitat Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.
21.
Zurück zum Zitat The Examination Committee of Criteria for Metabolic Syndrome. The definition and criteria of metabolic syndrome. J Jpn Soc Intern Med. 2005;94:794–809.CrossRef The Examination Committee of Criteria for Metabolic Syndrome. The definition and criteria of metabolic syndrome. J Jpn Soc Intern Med. 2005;94:794–809.CrossRef
22.
Zurück zum Zitat Suzuki R, Watanabe S, Hirai Y, Akiyama K, Nishide T, Matsushima Y, et al. Abdominal wall fat index, estimated by ultrasonography, for assessment of the ratio of visceral fat to subcutaneous fat in the abdomen. Am J Med. 1993;95:309–14.PubMedCrossRef Suzuki R, Watanabe S, Hirai Y, Akiyama K, Nishide T, Matsushima Y, et al. Abdominal wall fat index, estimated by ultrasonography, for assessment of the ratio of visceral fat to subcutaneous fat in the abdomen. Am J Med. 1993;95:309–14.PubMedCrossRef
23.
Zurück zum Zitat Nakanishi S, Matsuura B, Hirooka M, Ueda T, Niiya T, Furukawa S, et al. Clinical usefulness of quantitative evaluation of visceral fat by ultrasonography. J Med Ultrason. 2007;34:151–7.CrossRef Nakanishi S, Matsuura B, Hirooka M, Ueda T, Niiya T, Furukawa S, et al. Clinical usefulness of quantitative evaluation of visceral fat by ultrasonography. J Med Ultrason. 2007;34:151–7.CrossRef
24.
Zurück zum Zitat Kawamoto R, Ohtsuka N, Nakamura S, Ninomiya D, Inoue A. Preperitoneal fat thickness by ultrasonography and obesity-related disorders. J Med Ultrason. 2007;34:93–9.CrossRef Kawamoto R, Ohtsuka N, Nakamura S, Ninomiya D, Inoue A. Preperitoneal fat thickness by ultrasonography and obesity-related disorders. J Med Ultrason. 2007;34:93–9.CrossRef
25.
Zurück zum Zitat Hirooka M, Kumagi T, Kurose K, Nakanishi S, Michitaka K, Matsuura B, et al. A technique for the measurement of visceral fat by ultrasonography: comparison of measurements by ultrasonography and computed tomography. Intern Med. 2005;44:794–9.PubMedCrossRef Hirooka M, Kumagi T, Kurose K, Nakanishi S, Michitaka K, Matsuura B, et al. A technique for the measurement of visceral fat by ultrasonography: comparison of measurements by ultrasonography and computed tomography. Intern Med. 2005;44:794–9.PubMedCrossRef
26.
Zurück zum Zitat Lonardo A, Bellini M, Tartoni P, Tondelli E. The bright liver syndrome: prevalence and determinants of a bright liver echopattern. Int J Gastroenterol Hepatol Res. 1997;29:351–6. Lonardo A, Bellini M, Tartoni P, Tondelli E. The bright liver syndrome: prevalence and determinants of a bright liver echopattern. Int J Gastroenterol Hepatol Res. 1997;29:351–6.
27.
Zurück zum Zitat Bureau HS (ed.) Outline of National Health and Nutrition Survey. 2008. Bureau HS (ed.) Outline of National Health and Nutrition Survey. 2008.
28.
Zurück zum Zitat Koda M, Kawakami M, Murawaki Y, Senda M. The impact of visceral fat in nonalcoholic fatty liver disease: cross-sectional and longitudinal studies. J Gastroenterol. 2007;42:897–903.PubMedCrossRef Koda M, Kawakami M, Murawaki Y, Senda M. The impact of visceral fat in nonalcoholic fatty liver disease: cross-sectional and longitudinal studies. J Gastroenterol. 2007;42:897–903.PubMedCrossRef
29.
Zurück zum Zitat Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114:147–52.PubMed Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114:147–52.PubMed
30.
Zurück zum Zitat Schaffler A, Scholmerich J, Buchler C. Mechanisms of disease: adipocytokines and visceral adipose tissue: emerging role in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol. 2005;2:273–80.PubMedCrossRef Schaffler A, Scholmerich J, Buchler C. Mechanisms of disease: adipocytokines and visceral adipose tissue: emerging role in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol. 2005;2:273–80.PubMedCrossRef
31.
Zurück zum Zitat Stranges S, Dorn JM, Muti P, Freudenheim JL, Farinaro E, Russell M, et al. Body fat distribution, relative weight, and liver enzyme levels: a population-based study. Hepatology. 2004;39:754–63.PubMedCrossRef Stranges S, Dorn JM, Muti P, Freudenheim JL, Farinaro E, Russell M, et al. Body fat distribution, relative weight, and liver enzyme levels: a population-based study. Hepatology. 2004;39:754–63.PubMedCrossRef
32.
Zurück zum Zitat Jensen MD. Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab. 2008;93:S57–63.PubMedCrossRef Jensen MD. Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab. 2008;93:S57–63.PubMedCrossRef
33.
Zurück zum Zitat Suganami T, Tanimoto-Koyama K, Nishida J, Itoh M, Yuan X, Mizuarai S, et al. Role of the toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol. 2007;27:84–91.PubMedCrossRef Suganami T, Tanimoto-Koyama K, Nishida J, Itoh M, Yuan X, Mizuarai S, et al. Role of the toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol. 2007;27:84–91.PubMedCrossRef
34.
Zurück zum Zitat Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117:175–84.PubMedCrossRef Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117:175–84.PubMedCrossRef
35.
Zurück zum Zitat Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51:679–89.PubMedCrossRef Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51:679–89.PubMedCrossRef
36.
Zurück zum Zitat Yin M, Wheeler MD, Kono H, Bradford BU, Gallucci RM, Luster MI, et al. Essential role of tumor necrosis factor alpha in alcoholic-induced liver injury in mice. Gastroenterology. 1999;117:942–52.PubMedCrossRef Yin M, Wheeler MD, Kono H, Bradford BU, Gallucci RM, Luster MI, et al. Essential role of tumor necrosis factor alpha in alcoholic-induced liver injury in mice. Gastroenterology. 1999;117:942–52.PubMedCrossRef
37.
Zurück zum Zitat Ruiz AG, Casafont F, Crespo J, Cayon A, Mayorga M, Estebanez A, et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in pathogenesis of non-alcoholic steatohepatitis. Obes Surg. 2007;17:1374–80.PubMedCrossRef Ruiz AG, Casafont F, Crespo J, Cayon A, Mayorga M, Estebanez A, et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in pathogenesis of non-alcoholic steatohepatitis. Obes Surg. 2007;17:1374–80.PubMedCrossRef
38.
Zurück zum Zitat Manco M, Marcellini M, Giannone G, Nobili V. Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric non-alcoholic fatty liver disease. Am J Clin Pathol. 2007;127:954–60.PubMedCrossRef Manco M, Marcellini M, Giannone G, Nobili V. Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric non-alcoholic fatty liver disease. Am J Clin Pathol. 2007;127:954–60.PubMedCrossRef
39.
Zurück zum Zitat Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology. 2003;125:1796–807.PubMedCrossRef Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology. 2003;125:1796–807.PubMedCrossRef
40.
Zurück zum Zitat Okumura K, Ikejima K, Kon K, Abe W, Yamashina S, Enomoto N, et al. Exacerbation of dietary steatohepatitis and fibrosis in obese, diabetic KK-A(y) mice. Hepatol Res. 2006;36:217–28.PubMedCrossRef Okumura K, Ikejima K, Kon K, Abe W, Yamashina S, Enomoto N, et al. Exacerbation of dietary steatohepatitis and fibrosis in obese, diabetic KK-A(y) mice. Hepatol Res. 2006;36:217–28.PubMedCrossRef
Metadaten
Titel
Usefulness of differentiating metabolic syndrome into visceral fat type and subcutaneous fat type using ultrasonography in Japanese males
verfasst von
Masahiro Sogabe
Toshiya Okahisa
Shingo Hibino
Akira Yamanoi
Publikationsdatum
01.03.2012
Verlag
Springer Japan
Erschienen in
Journal of Gastroenterology / Ausgabe 3/2012
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-011-0489-4

Weitere Artikel der Ausgabe 3/2012

Journal of Gastroenterology 3/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.